USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CELSENSE, INC.
Address:
603 STANWIX STREET
SUITE 348
PITTSBURGH, PA 15222-
Phone:
N/A
URL:
N/A
EIN:
120298487
DUNS:
798793548
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $273,009.00 1
STTR Phase I $511,442.00 2

Award List:

Analysis of Cell Sense Labeled Human Cells

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$273,009.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cellular therapeutics represent great potential for curing and alleviating symptoms associated with debilitating human diseases, such as cancer, cardiovascular disease, and neurological disorders. Currently, no versatil e methodology for tracking cellular… More

Dual Mode Nanoemulsions for 19F MRI and Fluorescence Detection

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$132,282.00
Agency:
HHS
Principal Investigator:
Research Institution:
DUQUESNE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Recently, scientists at Carnegie Mellon University (CMU) have invented a compelling technology that makes transplanted cells visible with magnetic resonance imaging (MRI). Cells of interest are labeled ex vivo with a n ovel perfluoropolyether (PFPE) nanoemulsion… More

Platform for myocardial infarct MRI and delivery of therapeutics

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$379,160.00
Agency:
HHS
Principal Investigator:
Eric T. Ahrens – 412-268-5105
Research Institution:
CELSENSE, INC.
RI Contact:
Abstract:
Myocardial infarction (MI) afflicts more than one million persons per year in the United States alone. MI results in permanent left ventricle (LV) scarring that causes diminished pump efficiency and, commonly, heart failure. Towards reduction or elimination of scarring, there is increasing interest… More